Compared with the CE group, GA treatment significantly reduced hepatic cysts volume (by approximately 42.36%; Ρ < 0.05; Fig 3b and 3c) and decreased serum levels of the key pro-fibrotic cytokine TGF-β1 (Ρ < 0.01; Fig 3d). This evidence concerns the gene TGFB1 and Hepatic cysts.